The Physician in Anthropic's Boardroom
Vas Narasimhan runs Novartis, a top-five drugmaker facing a patent cliff. In April he took a board seat at Anthropic - betting AI's fastest payoff is in medicine.
On April 14, 2026, Anthropic added Vas Narasimhan - a physician and the chief executive of Novartis - to its board of directors, and the arithmetic of that board changed with him: directors chosen by the company's Long-Term Benefit Trust now made up a majority. The new director was not a technologist. His reason for taking the seat was a claim about where artificial intelligence pays off first. "In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines," he said.
From Medicine To The Pipeline
Narasimhan's authority on that claim is earned, not borrowed. He holds a medical degree from Harvard and a master's in public policy from its Kennedy School, and began his career on HIV/AIDS, malaria and tuberculosis programs in India, Africa and South America. He joined Novartis in 2005 and rose through its development organization - running vaccines development, then pharmaceuticals development, then serving as global head of drug development and chief medical officer - before the board made him chief executive in 2018. Over that career he has overseen the approval of more than 35 novel medicines and vaccines. Daniela Amodei, Anthropic's co-founder and president, cited exactly that record, saying he had "overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries."
The Case For Convergence
The board seat is a statement about strategy. Drug discovery is slow, expensive and mostly failure; a medicine that reaches patients is the survivor of thousands that do not. Narasimhan's wager is that AI compresses the earliest and most uncertain steps - reading disease biology, proposing molecules - rather than merely automating paperwork. He framed his role in those terms: "Anthropic is setting the standard for how AI should be developed to benefit humanity, and I'm honored to join the Board and contribute to its mission." Anthropic has been building toward healthcare and life sciences, and seating a drug-industry chief executive on its board formalizes the direction.
The Patent Cliff Ahead
The complication is at his day job, not his new board. Novartis is heading into a wave of patent expirations, including on the heart-failure drug Entresto, that will open top-selling medicines to generic competition - the recurring cliff every large drugmaker eventually walks up to. The AI thesis, whatever it yields, will not arrive in time to refill that gap; new medicines take years, and the losses are near. Asked in July 2026 about his own plans amid the pressure, Narasimhan was terse: "No change of plans for me." He is staying to run Novartis through the expirations, and through the trial readouts and launches meant to offset them - while sitting on the board of the AI company he is betting will change how the next generation of medicines is found.